Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Clinical stage biotech company Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has released a new investor presentation as the company presents at the Ord Minnett Healthcare Forum.

Recce is at the forefront of developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs and emerging viral pathogens.

The company's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327, RECCE® 435, and RECCE® 529. These innovative therapies have the potential to overcome the challenges posed by bacterial and viral mutations that have rendered traditional antibiotics less effective.

The company has multiple near-term clinical readouts due, and multiple clinical indications and formulations in Phase I and Phase II addressing unmet medical needs in sepsis, UTI, burn wounds and diabetic foot ulcer infections.

Read the full article here: https://www.proactiveinvestors.com.au/companies/news/1031461/recce-pharmaceuticals-presents-at-ord-minnett-healthcare-forum-1031461.html

Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum